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Objectives: In an innovative therapeutic exploitation against antibiotic-resistant Streptococcus
pneumoniae, here we have evaluated the in vitro activity of a purified bacterially-encoded cell wall lytic
enzyme, LytA (the major pneumococcal autolysin), and compared it with those of Cpl-1 and Pal
(pneumococcal phage lytic enzymes) and two antibiotics versus four pneumococcal strains.
Methods: Two serotype 3, penicillin-susceptible strains and two penicillin-resistant (serotypes 19F and
19A, respectively) S. pneumoniae clinical isolates were used. The effect of several combinations of
lytic enzymes and antibiotics (cefotaxime and moxifloxacin) was studied by chequerboard and time–
kill assays, the latter at concentrations of 0.253 MIC.
Results: LytA was more active than Cpl-1 and Pal. By the chequerboard technique, the combination of
LytA and cefotaxime was synergistic for one of the two cefotaxime-resistant strains studied. The com-
bined use of Cpl-1 and Pal was synergistic for three of the four strains, as was Cpl-1 with antibiotics
for two of the three strains studied. In the time–kill assays, after 5 h of exposure to LytA, Cpl-1 or Pal,
the mean differences in colony counts versus controls were 23.55, 22.66 and 22.71 log10 cfu/mL,
respectively. The combination of LytA/Pal reduced the bacterial inoculum >2 log units for three of the
four strains. LytA combined with cefotaxime or moxifloxacin achieved >3 log units decrease for the
strains tested. Particularly, a strong synergism was observed with LytA/cefotaxime for one cefotaxime-
resistant meningeal strain. LytA/moxifloxacin was synergistic for the quinolone-resistant strain when
tested by time–kill methodology, and just close to synergistic (fractional inhibitory concentration
index of 0.58) by the chequerboard technique. Antagonism was not observed for any combination
when assayed by either method.
Conclusions: LytA, Cpl-1 or Pal, alone or in combination, might prove to be effective in combination
therapy, as well as in monotherapy against S. pneumoniae. These results suggest avenues of research
to study the cell wall lytic enzymes as anti-pneumococcal therapeutic agents.
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Introduction
New therapeutic strategies are required for treating drug-resistant
Streptococcus pneumoniae infections. The potential use of purified
phage lytic enzymes alone, in combination or together with
antibiotics is a recent line of investigation.1–3 The pneumococcal
lytic phages Cp-1 and Dp-1 encode, respectively, the lytic
enzymes named Cpl-1 and Pal.4 Purified preparations of Cpl-1
and/or Pal have been used successfully as therapeutic agents in
animal models of nasopharyngeal carriage, sepsis and endocarditis
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induced by S. pneumoniae strains.5–7 Furthermore S. pneumoniae
contains four well-characterized cell wall hydrolases (LytA,
LytB, LytC and Pce),4 which could also be of interest as thera-
peutic agents.
In this report, we show a novel exploitation of purified LytA
for the chemotherapeutic intervention of S. pneumoniae infec-
tions. We have evaluated whether the combined use of lytic
enzymes (LytA, Cpl-1 and Pal) or an enzyme and one conven-
tional antibiotic (cefotaxime or moxifloxacin) exhibit a synergis-
tic effect against several S. pneumoniae strains.
Materials and methods
Bacterial strains, lytic enzymes and antibiotics
Four pneumococcal clinical isolates were tested. Two were
penicillin-susceptible (MIC 0.01 mg/L) and belonged to serotype
3 (AR33118 and FL5629) and two were penicillin-resistant (MIC 4
and 8 mg/L), one of serotype 19F (MJD3693) and the other of sero-
type 19A (South African strain 8249). LytA, Cpl-1 and Pal were
purified by affinity chromatography in DEAE-cellulose as previously
described for other choline-binding enzymes.8 Cefotaxime was pur-
chased from Sigma Chemicals Co. (St Louis, MO, USA) and moxi-
floxacin (Bayer AG, Leverkusen, Germany) was kindly provided by
the manufacturer.
MIC determination
The MICs of LytA, Cpl-1, Pal, cefotaxime and moxifloxacin
were determined by broth microdilution following the CLSI
methodology.9
Chequerboard broth microdilution method for synergy
testing
Interactions between two enzymes and between one enzyme and
one antibiotic were tested by the chequerboard method10 in microti-
tre plates in the same broth as used for MIC determinations. All
compounds were tested alone and in combination at seven concen-
trations that usually ranged from one-sixteenth to four times
the MIC. Inocula were prepared at a bacterial concentration of
5  104 cfu per well. The final volume was 100 mL per well.
Trays were aerobically incubated at 358C for 22 h. The results
were interpreted by the pattern they showed on an isobologram and
the fractional inhibitory concentration (FIC) for each compound was
calculated. The FIC index (FICI) was determined by summing the
separate FICs for each of the compounds present in that well.
Interactions between any enzyme and cefotaxime or moxifloxacin
were not assessed against organisms fully susceptible to these
antibiotics. Each test was performed at three separate times and
the FICI values were expressed as means. Synergy was defined by an
FICI 0.5, antagonism by an FICI .4.0 and no interaction by an
FICI .0.5–4.
Time–kill determinations
Selected combinations were studied using time–kill kinetic analysis;
particularly for the four clinical isolates for which the
LytA-containing combinations achieved FICI ,0.8. The assays
were performed in broth with the same composition as used for
MIC determinations with each compound alone or in combination at
0.25 MIC. Bacteria were grown in broth to mid-log phase at a
final titre of 107 cfu/mL. Inoculated tubes were incubated at 358C.
Samples (100 mL) were removed after 1, 3 and 5 h and plated on
blood agar plates for titre determination. Each assay was performed
in duplicate. Synergy was defined as a 2 log10 decrease in cfu/mL
between the combination and its most active agent, and the number
of viable organisms in the presence of the combination was
2 log10 cfu/mL below the starting inoculum.
Results
The MIC values (LytA, Cpl-1, Pal, cefotaxime and moxifloxa-
cin) were: strain MJD3693 (16, 32, 256, 4 and 0.25 mg/L),
strain AR33118 (8, 16, 32, 0.01 and 0.12 mg/L), strain 8249
(2, 8, 128, 4 and 0.25 mg/L) and strain FL5629 (4, 16, 32,
0.01 and 8 mg/L).
The interactions of LytA, Cpl-1, Pal, cefotaxime and moxi-
floxacin, as determined by the chequerboard technique, are
shown in Table 1. The combination of LytA with Cpl-1 was
indifferent against the four strains, although for strain FL5629
an FICI of 0.67 was achieved. Synergy between LytA and Pal
was not found for the four strains, but the FICIs were lower than
0.8. The combination of LytA with cefotaxime was synergistic
for strain MJD3693, one cefotaxime-resistant strain (FICI ¼
0.18), whereas it was not for the second cefotaxime-resistant
isolate, strain 8249 (FICI ¼ 0.71). For the moxifloxacin-resistant
strain (FL5629), synergy between LytA and moxifloxacin was
not observed (FICI ¼ 0.58).
Synergy was also found with the following combinations:
Cpl-1 with Pal for three out of the four strains tested; Cpl-1 with
cefotaxime for one of the two cefotaxime-resistant strains tested
(strain MJD3693) and Cpl-1 with moxifloxacin for the
quinolone-resistant isolate (strain FL5629). The combination of
Pal with either cefotaxime or moxifloxacin did not prove to be
synergistic against the antibiotic-resistant strains. Antagonism
was not observed for any combination, against any of the strains
tested.
Figure 1 shows the results of the time–kill experiments
for LytA, Pal, Cpl-1, cefotaxime and moxifloxacin at a fixed
concentration of 0.25 MIC, alone and in combination.





MJD3693 AR33118 8249 FL5629
LytA Cpl-1 1.27 1.06 0.91 0.67
Pal 0.54 0.79 0.57 0.55
cefotaxime 0.18 ND 0.71 ND
moxifloxacin ND ND ND 0.58
Cpl-1 Pal 0.50 0.42 0.34 0.60
cefotaxime 0.41 ND 0.54 ND
moxifloxacin ND ND ND 0.42
Pal cefotaxime 0.62 ND 0.56 ND
moxifloxacin ND ND ND 1.05
Synergistic combinations are in bold; combinations that were also studied by
time–kill method are in italics.
ND, not determined (as the organisms were fully susceptible to the antibiotics).
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No combination was antagonistic by the time–kill assays.
After 1, 3 and 5 h of single exposure to LytA and Pal, the
mean differences in colony counts for the four strains tested
versus controls were 22.24, 23.47 and 23.55, and 22.89,
23.19 and 22.71 log10 cfu/mL. On the other hand, Cpl-1
alone showed differences in bacterial titres versus controls of
21.64, 22.71 and 22.66 log10 cfu/mL for the strain tested. In
contrast, at all time points, the differences in colony counts
achieved by cefotaxime or moxifloxacin alone were lower than
20.77 log10 cfu/mL versus controls for the strains tested.
Bactericidal activity (reduction of 3 log10 cfu/mL from the
initial inoculum) was mostly achieved with LytA and Pal
alone for one of the four strains (strain 8249). Furthermore,
LytA/Pal was also bactericidal for two out of the four strains
(strains MJD3693 and 8249). LytA/cefotaxime also showed
bactericidal activity for the two strains studied (strains
MJD3693 and 8249), as did LytA/moxifloxacin for the single
strain studied (strain FL5629).
Synergistic effects were achieved after 5 h of exposure to
LytA/cefotaxime against strain MJD3693 (2.48 log10 decrease in
cfu/mL between the combination and LytA) and to LytA/
moxifloxacin against strain FL5629 (2.42 log10 decrease in cfu/
mL between the combination and LytA). For these two strains,
these enzyme/antibiotic combinations showed FICIs of 0.18 and
0.58, respectively. Therefore, only in the first case, the FICI sup-
ported a synergistic effect when applying stringent criteria.
Although no synergism was found with LytA combined with
cefotaxime in the other cefotaxime-resistant strain (8249), this
strain was highly susceptible to LytA alone (more than 4 log10
reduction) making it difficult to demonstrate such as effect.
Discussion
The results of the present study confirm the superior in vitro
activity of LytA compared with those of Cpl-1 and Pal in terms
of a lower MIC value for several S. pneumoniae strains. In con-
trast to the antibiotic activity, LytA and the other two enzymes
reduced the bacterial inoculum very rapidly at concentrations
of 0.25 MIC. Furthermore, one cefotaxime-resistant (MIC
4 mg/L) strain (8249) had a LytA MIC of 2 mg/L, being rapidly
bactericidal at concentrations of 0.25 MIC, and such activity
was maintained up to 5 h. Our results show that LytA displayed
a potent synergistic effect with cefotaxime against one of the
two cefotaxime-resistant strains by the two techniques used
(MJD3693). Furthermore, LytA combined with moxifloxacin
was also synergistic against the moxifloxacin-resistant strain
tested (FL5629), but only by time–kill assays although the FICI
(0.58) of such a combination was close to 0.5. For the second
cefotaxime-resistant strain (8249), it was not possible to demon-
strate synergism with LytA/cefotaxime, probably due to the
strong bactericidal activity of LytA alone. By the chequerboard
technique, no synergism between Cpl-1 and LytA was observed
for any strain. The combination of Cpl-1 plus Pal resulted in
synergism against three out of the four pneumococcal strains
tested. Moreover, this synergistic effect has been confirmed with
a sepsis model:5 the combination of Cpl-1 and Pal was more
effective than either agent alone in prolonging survival in exper-
imental penicillin-resistant pneumococcal sepsis in mice. In our
experiments, the combination of Cpl-1 and one antibiotic, cefo-
taxime or moxifloxacin, indicated synergism, respectively, for
one cefotaxime-resistant strain (MJD3693; FICI ¼ 0.41) and for
the moxifloxacin-resistant strain (FL5629; FICI ¼ 0.42). This
latter finding was in contrast to a previous report, in which
Cpl-1 showed no interaction when combined with levofloxacin.3
Noticeably, the synergistic effect of Cpl-1 combined with cefo-
taxime was shown against the same cefotaxime-resistant isolate
for which LytA combined with cefotaxime was synergistic,
but the combination of Cpl-1/cefotaxime against the other
cefotaxime-resistant strain (8249) achieved an FICI of 0.54,
close to a synergistic value. On the other hand, the combination
of Pal and cefotaxime demonstrated no interaction for the two
pneumococci tested.
The combinations of LytA giving FICIs ,0.8 were con-
firmed with the more dynamic interaction provided by the time–
kill kinetic study system using one-fourth times the MIC of each
agent alone or combined. The results of time–kill kinetic curves
confirmed the chequerboard data in that none of the combi-
nations resulted in antagonism and seven out of the eight time–
kill tests showed the same results as those obtained by the
chequerboard technique (synergism with LytA/cefotaxime against
the meningeal cefotaxime-resistant strain, and indifference with
Figure 1. Time–kill assays with five compounds each at 0.25 MIC alone
and in combination (solid lines) against four pneumococcal strains. (a–d)
Strains MJD3693, AR33118, 8249 and FL5629, respectively. LytA, open
diamonds; Pal, open squares; combination, open circles. (e and f) Strains
MJD3693 and 8249, respectively. LytA, open diamonds; cefotaxime, filled
squares; combination, open circles. (g) Strain FL5629. LytA, open
diamonds; Cpl-1, open triangles; combination, open circles. (h) Strain
FL5629. LytA, open diamonds; moxifloxacin, filled triangles; combination,
open circles. All control values are represented by filled circles.
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the rest of the combinations). The unique discrepancy was
shown for the combination of LytA/moxifloxacin that was syner-
gistic by time–kill testing and indifferent by the chequerboard
procedure, but having an FICI of 0.58.
We provide the first evidence that the exogenous addition of
purified LytA may well be considered a good candidate for a
new generation of antibacterial agents to treat antibiotic-resistant
S. pneumoniae infections. In an era of global spreading of
antibiotic-resistant pneumococci, the potential role of cell wall
hydrolases, such as LytA, Cpl-1 and Pal, as therapeutic agents
warrants further investigation.
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